BSX Boston Scientific Loading...

From SYK earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
21:30
Jan 29 ◎
Jason Beach SYK Q4 FY25 call
Inari peripheral vascular destocking was heavier than expected in Q4 but is minimal by Q1; high-teens procedural growth shows strong underlying PE thrombectomy demand, a positive read-across to competing players. — If destocking clears by Q1, Stryker's peripheral vascular business re-accelerates, intensifying competition in the pulmonary embolism/thrombectomy market.
BSX
MED

About BSX Analyst Coverage

Buzzberg tracks BSX (Boston Scientific) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Jason Beach.